Review article: Breath analysis in inflammatory bowel diseases

Alimentary Pharmacology and Therapeutics

Volumn 41, Issue 4, 2015, Pages 329-341

  Kurada, S ^a   Alkhouri, N ^b   Fiocchi, C ^b,c   Dweik, R ^b,d   Rieder, F ^c  

^a Medicine Institute ^*  (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c Digestive Disease Institute   (United States)

^d Respiratory Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 OCTENE; CYTOKINE; ETHANE; HYDROGEN SULFIDE; INTERLEUKIN 1BETA; ISOPRENE; METHANE; NITRIC OXIDE; PENTANE; PROPANE; VOLATILE ORGANIC COMPOUND; BIOLOGICAL MARKER;

AREA UNDER THE CURVE; ARTICLE; BREATH ANALYSIS; CLINICAL PRACTICE; CROHN DISEASE; DISEASE ACTIVITY; DISEASE COURSE; FEASIBILITY STUDY; GASTROINTESTINAL DISEASE; HUMAN; INFLAMMATORY BOWEL DISEASE; MASS SPECTROMETRY; METABOLOME; METABOLOMICS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; AGED; CHILD; CLASSIFICATION; DIET; FEMALE; HEALTH STATUS INDICATOR; INFLAMMATORY BOWEL DISEASES; LIVER; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PRESCHOOL CHILD; PROCEDURES;

AGED; BIOLOGICAL MARKERS; BREATH TESTS; CHILD; CHILD, PRESCHOOL; CYTOKINES; DIET; FEMALE; HEALTH STATUS INDICATORS; HUMANS; INFLAMMATORY BOWEL DISEASES; LIVER; MALE; METABOLOME; MIDDLE AGED; VOLATILE ORGANIC COMPOUNDS;

EID: 84921435429     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13050     Document Type: Article

References (87)

1. Van Assche G, Dignass A, Panes J, et al,. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis 2010; 4: 7-27.
2. Vavricka SR, Spigaglia SM, Rogler G, et al,. Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 496-505.
3. Silverberg MS, Satsangi J, Ahmad T, et al,. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19 (Suppl A): 5A-36A.
4. Moum B, Ekbom A, Vatn MH, et al,. Inflammatory bowel disease: re-evaluation of the diagnosis in a prospective population based study in south eastern Norway. Gut 1997; 40: 328-32.
5. Regueiro M, Kip KE, Schraut W, et al,. Crohn's disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resection. Inflamm Bowel Dis 2011; 17: 118-26.
6. Lahiff C, Safaie P, Awais A, et al,. The Crohn's disease activity index (CDAI) is similarly elevated in patients with Crohn's disease and in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2013; 37: 786-94.
7. Sipponen T, Nuutinen H, Turunen U, Farkkila M,. Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES-CD. Inflamm Bowel Dis 2010; 16: 2131-6.
8. Anand V, Russell AS, Tsuyuki R, Fedorak R,. Perinuclear antineutrophil cytoplasmic autoantibodies and anti-Saccharomyces cerevisiae antibodies as serological markers are not specific in the identification of Crohn's disease and ulcerative colitis. Can J Gastroenterol 2008; 22: 33-6.
9. Ferrante M, Henckaerts L, Joossens M, et al,. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007; 56: 1394-403.
10. Papadakis KA, Yang H, Ippoliti A, et al,. Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations. Inflamm Bowel Dis 2007; 13: 524-30.
11. Rieder F, Schleder S, Wolf A, et al,. Association of the novel serologic anti-glycan antibodies anti-laminarin and anti-chitin with complicated Crohn's disease behavior. Inflamm Bowel Dis 2010; 16: 263-74.
12. Vermeire S, Van Assche G, Rutgeerts P,. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006; 55: 426-31.
13. Vermeire S, Van Assche G, Rutgeerts P,. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 661-5.
14. Sherwood RA,. Faecal markers of gastrointestinal inflammation. J Clin Pathol 2012; 65: 981-5.
15. Kopylov U, Rosenfeld G, Bressler B, Seidman E,. Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease. Inflamm Bowel Dis 2014; 20: 742-56.
16. Henderson P, Anderson NH, Wilson DC,. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2014; 109: 637-45.
17. Blotiere PO, Weill A, Ricordeau P, Alla F, Allemand H,. Perforations and haemorrhages after colonoscopy in 2010: a study based on comprehensive French health insurance data (SNIIRAM). Clin Res Hepatol Gastroenterol 2014; 38: 112-7.
18. Friedman S, Cheifetz AS, Farraye FA, et al,. Factors that affect adherence to surveillance colonoscopy in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 534-9.
19. Jensen MD, Ormstrup T, Vagn-Hansen C, Ostergaard L, Rafaelsen SR,. Interobserver and intermodality agreement for detection of small bowel Crohn's disease with MR enterography and CT enterography. Inflamm Bowel Dis 2011; 17: 1081-8.
20. D'Haens GR,. Top-down therapy for IBD: rationale and requisite evidence. Nat Rev Gastroenterol Hepatol 2010; 7: 86-92.
21. Devlin SM, Panaccione R,. Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. Med Clin North Am 2010; 94: 1-18.
22. Yoshida M, Hatano N, Nishiumi S, et al,. Diagnosis of gastroenterological diseases by metabolome analysis using gas chromatography-mass spectrometry. J Gastroenterol 2012; 47: 9-20.
23. Bouatra S, Aziat F, Mandal R, et al,. The human urine metabolome. PLoS ONE 2013; 8: e73076.
24. Yonezawa K, Nishiumii S, Kitamoto-Matsuda J, et al,. Serum and tissue metabolomics of head and neck cancer. Cancer Genomics Proteomics 2013; 10: 233-8.
25. Duarte IF, Rocha CM, Gil AM,. Metabolic profiling of biofluids: potential in lung cancer screening and diagnosis. Expert Rev Mol Diagn 2013; 13: 737-48.
26. Gahleitner F, Guallar-Hoyas C, Beardsmore CS, Pandya HC, Thomas CP,. Metabolomics pilot study to identify volatile organic compound markers of childhood asthma in exhaled breath. Bioanalysis 2013; 5: 2239-47.
27. Balderas C, Ruperez FJ, Ibanez E, et al,. Plasma and urine metabolic fingerprinting of type 1 diabetic children. Electrophoresis 2013; 34: 2882-90.
28. Wang J, Li Z, Chen J, et al,. Metabolomic identification of diagnostic plasma biomarkers in humans with chronic heart failure. Mol BioSyst 2013; 9: 2618-26.
29. Fanos V, Fanni C, Ottonello G, et al,. Metabolomics in adult and pediatric nephrology. Molecules 2013; 18: 4844-57.
30. Denkert C, Budczies J, Weichert W, et al,. Metabolite profiling of human colon carcinoma-deregulation of TCA cycle and amino acid turnover. Mol Cancer 2008; 7: 72.
31. Wu H, Xue R, Lu C, et al,. Metabolomic study for diagnostic model of oesophageal cancer using gas chromatography/mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 3111-7.
32. Wu H, Xue R, Tang Z, et al,. Metabolomic investigation of gastric cancer tissue using gas chromatography/mass spectrometry. Anal Bioanal Chem 2010; 396: 1385-95.
33. Wu H, Xue R, Dong L, et al,. Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry. Anal Chim Acta 2009; 648: 98-104.
34. Kobayashi T, Nishiumi S, Ikeda A, et al,. A novel serum metabolomics-based diagnostic approach to pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2013; 22: 571-9.
35. Martin FP, Rezzi S, Philippe D, et al,. Metabolic assessment of gradual development of moderate experimental colitis in IL-10 deficient mice. J Proteome Res 2009; 8: 2376-87.
36. Baur P, Martin FP, Gruber L, et al,. Metabolic phenotyping of the Crohn's disease-like IBD etiopathology in the TNF(DeltaARE/WT) mouse model. J Proteome Res 2011; 10: 5523-35.
37. Zhang Y, Lin L, Xu Y, et al,. 1H NMR-based spectroscopy detects metabolic alterations in serum of patients with early-stage ulcerative colitis. Biochem Biophys Res Commun 2013; 433: 547-51.
38. Williams HR, Willsmore JD, Cox IJ, et al,. Serum metabolic profiling in inflammatory bowel disease. Dig Dis Sci 2012; 57: 2157-65.
39. Stephens NS, Siffledeen J, Su X, et al,. Urinary NMR metabolomic profiles discriminate inflammatory bowel disease from healthy. J Crohns Colitis 2013; 7: e42-8.
40. Bjerrum JT, Nielsen OH, Hao F, et al,. Metabonomics in ulcerative colitis: diagnostics, biomarker identification, and insight into the pathophysiology. J Proteome Res 2010; 9: 954-62.
41. Arasaradnam RP, Ouaret N, Thomas MG, et al,. A novel tool for noninvasive diagnosis and tracking of patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 999-1003.
42. Phillips M, Greenberg J, Cataneo RN,. Effect of age on the profile of alkanes in normal human breath. Free Radic Res 2000; 33: 57-63.
43. Arasaradnam RP, Covington J, Nwokolo CU,. Editorial: metabolomic analysis of breath volatile organic compounds-a new scent for inflammatory bowel disease. Aliment Pharmacol Ther 2014; 40: 732-3.
44. Wilson AD, Baietto M,. Applications and advances in electronic-nose technologies. Sensors (Basil) 2009; 9: 5099-148.
45. Fens N, van der Schee MP, Brinkman P, Sterk PJ,. Exhaled breath analysis by electronic nose in airways disease. Established issues and key questions. Clin Exp Allergy 2013; 43: 705-15.
46. Cikach FS Jr, Dweik RA,. Cardiovascular biomarkers in exhaled breath. Prog Cardiovasc Dis 2012; 55: 34-43.
47. Ajibola OA, Smith D, Spanel P, Ferns GA,. Effects of dietary nutrients on volatile breath metabolites. J Nutr Sci 2013; 2: e34.
48. Hauschild AC, Baumbach JI, Baumbach J,. Integrated statistical learning of metabolic ion mobility spectrometry profiles for pulmonary disease identification. Genet Mol Res 2012; 11: 2733-44.
49. Pedroletti C, Hogman M, Merilainen P, et al,. Nitric oxide airway diffusing capacity and mucosal concentration in asthmatic schoolchildren. Pediatr Res 2003; 54: 496-501.
50. Grob NM, Aytekin M, Dweik RA,. Biomarkers in exhaled breath condensate: a review of collection, processing and analysis. J Breath Res 2008; 2: 037004.
51. Dent AG, Sutedja TG, Zimmerman PV,. Exhaled breath analysis for lung cancer. J Thorac Dis 2013; 5 (Suppl 5): S540-50.
52. Sethi S, Nanda R, Chakraborty T,. Clinical application of volatile organic compound analysis for detecting infectious diseases. Clin Microbiol Rev 2013; 26: 462-75.
53. Li J, Peng Y, Duan Y,. Diagnosis of breast cancer based on breath analysis: an emerging method. Crit Rev Oncol Hematol 2013; 87: 28-40.
54. Altomare DF, Di Lena M, Porcelli F, et al,. Exhaled volatile organic compounds identify patients with colorectal cancer. Br J Surg 2013; 100: 144-50.
55. Tisch U, Schlesinger I, Ionescu R, et al,. Detection of Alzheimer's and Parkinson's disease from exhaled breath using nanomaterial-based sensors. Nanomedicine (Lond) 2013; 8: 43-56.
56. Ionescu R, Broza Y, Shaltieli H, et al,. Detection of multiple sclerosis from exhaled breath using bilayers of polycyclic aromatic hydrocarbons and single-wall carbon nanotubes. ACS Chem Neurosci 2011; 2: 687-93.
57. Pagonas N, Vautz W, Seifert L, et al,. Volatile organic compounds in uremia. PLoS ONE 2012; 7: e46258.
58. Samara MA, Tang WH, Cikach F Jr, et al,. Single exhaled breath metabolomic analysis identifies unique breathprint in patients with acute decompensated heart failure. J Am Coll Cardiol 2013; 61: 1463-4.
59. Alkhouri N, Eng K, Cikach F, et al,. Breathprints of childhood obesity: changes in volatile organic compounds in obese children compared with lean controls. Pediatr Obes 2014; doi: 10.1111/j.2047-6310.2014.221.x. [Epub ahead of print].
60. Cikach FS Jr, Tonelli AR, Barnes J, et al,. Breath analysis in pulmonary arterial hypertension. Chest 2014; 145: 551-8.
61. Dweik RA, Boggs PB, Erzurum SC, et al,. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011; 184: 602-15.
62. Alkhouri N, Cikach F, Eng K, et al,. Analysis of breath volatile organic compounds as a noninvasive tool to diagnose nonalcoholic fatty liver disease in children. Eur J Gastroenterol Hepatol 2014; 26: 82-7.
63. Hanouneh IA, Zein NN, Cikach F, et al,. The breathprints in patients with liver disease identify novel breath biomarkers in alcoholic hepatitis. Clin Gastroenterol Hepatol 2014; 12: 516-23.
64. Morisco F, Aprea E, Lembo V, et al,. Rapid "breath-print" of liver cirrhosis by proton transfer reaction time-of-flight mass spectrometry. A pilot study. PLoS ONE 2013; 8: e59658.
65. Khalid TY, Costello BDL, Ewen R, et al,. Breath volatile analysis from patients diagnosed with harmful drinking, cirrhosis and hepatic encephalopathy: a pilot study. Metabolomics 2013; 9: 938-48.
66. Dryahina K, Spanel P, Pospisilova V, et al,. Quantification of pentane in exhaled breath, a potential biomarker of bowel disease, using selected ion flow tube mass spectrometry. Rapid Commun Mass Spectrom 2013; 27: 1983-92.
67. Pelli MA, Trovarelli G, Capodicasa E, De Medio GE, Bassotti G,. Breath alkanes determination in ulcerative colitis and Crohn's disease. Dis Colon Rectum 1999; 42: 71-6.
68. Sedghi S, Keshavarzian A, Klamut M, Eiznhamer D, Zarling EJ,. Elevated breath ethane levels in active ulcerative colitis: evidence for excessive lipid peroxidation. Am J Gastroenterol 1994; 89: 2217-21.
69. Koek GH, Verleden GM, Evenepoel P, Rutgeerts P,. Activity related increase of exhaled nitric oxide in Crohn's disease and ulcerative colitis: a manifestation of systemic involvement? Respir Med 2002; 96: 530-5.
70. Patel N, Alkhouri N, Eng K, et al,. Metabolomic analysis of breath volatile organic compounds reveals unique breathprints in children with inflammatory bowel disease: a pilot study. Aliment Pharmacol Ther 2014; 40: 498-507.
71. McKay LF, Eastwood MA, Brydon WG,. Methane excretion in man-a study of breath, flatus, and faeces. Gut 1985; 26: 69-74.
72. Nitta H, Kinoyama M, Teramoto F, et al,. Exhaled carbon monoxide concentration is not elevated in patients with inflammatory bowel disease. Clin Exp Med 2007; 7: 77-81.
73. Krenke K, Peradzynska J, Lange J, et al,. Inflammatory cytokines in exhaled breath condensate in children with inflammatory bowel diseases. Pediatr Pulmonol 2014; 49: 1190-5.
74. Kokoszka J, Nelson RL, Swedler WI, Skosey J, Abcarian H,. Determination of inflammatory bowel disease activity by breath pentane analysis. Dis Colon Rectum 1993; 36: 597-601.
75. Kato K, Ishii Y, Mizuno S, et al,. Usefulness of rectally administering [1-(13)C]-butyrate for breath test in patients with active and quiescent ulcerative colitis. Scand J Gastroenterol 2007; 42: 207-14.
76. Qin X,. Etiology of inflammatory bowel disease: a unified hypothesis. World J Gastroenterol 2012; 18: 1708-22.
77. Hanauer SB,. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006; 12 (Suppl 1): S3-9.
78. Yin H, Xu L, Porter NA,. Free radical lipid peroxidation: mechanisms and analysis. Chem Rev 2011; 111: 5944-72.
79. Van Gossum A, Decuyper J,. Breath alkanes as an index of lipid peroxidation. Eur Respir J 1989; 2: 787-91.
80. Kessler W, Remmer H,. Generation of volatile hydrocarbons from amino acids and proteins by an iron/ascorbate/GSH system. Biochem Pharmacol 1990; 39: 1347-51.
81. Naito Y, Takagi T, Yoshikawa T,. Heme oxygenase-1: a new therapeutic target for inflammatory bowel disease. Aliment Pharmacol Ther 2004; 20 (Suppl 1): 177-84.
82. Yin H, Fang J, Liao L, Nakamura H, Maeda H,. Styrene-maleic acid copolymer-encapsulated CORM2, a water-soluble carbon monoxide (CO) donor with a constant CO-releasing property, exhibits therapeutic potential for inflammatory bowel disease. J Control Release 2014; 187: 14-21.
83. Pavlick KP, Laroux FS, Fuseler J, et al,. Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease. Free Radic Biol Med 2002; 33: 311-22.
84. Polag D, Leiss O, Keppler F,. Age dependent breath methane in the German population. Sci Total Environ 2014; 481: 582-7.
85. Flourie B, Pellier P, Florent C, et al,. Site and substrates for methane production in human colon. Am J Physiol 1991; 260: G752-7.
86. Levine J, Furne JK, Levitt MD,. Ashkenazi Jews, sulfur gases, and ulcerative colitis. J Clin Gastroenterol 1996; 22: 288-91.
87. Paschke KM, Mashir A, Dweik RA,. Clinical applications of breath testing. F1000 Med Rep 2010; 2: 56.